Antibodies in sera from Norwegian multiple sclerosis patients and the general population reacting with HTLV-1. A pilot study.
By using enzyme-linked immunosorbent assay, Western blot and passive agglutination we have performed a pilot study involving the testing of 349 sera from the general population of 3 coastal regions in southern Norway, 230 sera from multiple sclerosis patients from western Norway, 109 age- and sex-matched controls and 34 sera from patients with other neurological diseases, for antibodies to HTLV-I. About 2% and 4% of sera from the general population had antibodies reacting with HTLV-I in ELISA and Adult T-cell Leukemia Antigen by agglutination, respectively, whereas about 8% and 5% of the multiple sclerosis sera had such antibodies. In the general population antibodies were more frequent among young individuals and there appeared to be some prevalent regional differences. Western blot confirmatory tests showed that in some instances antibodies reacted with the gag proteins, in particular p19. The results obtained in this study do not indicate an association between HTLV-I and multiple sclerosis, although at this stage we cannot rule out that another retrovirus is involved.
Haaheim
L R
LR
Department of Microbiology and Immunology, Haukeland Hospital, University of Bergen, Norway.
Grønning
M
M
Nyland
H
H
D000372:Agglutination Tests; D015153:Blotting, Western; D015480:Deltaretrovirus Antibodies / Q000032:analysis*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D009103:Multiple Sclerosis / Q000276:immunology*; D009664:Norway; D016036:Seroepidemiologic Studies
D015480:Deltaretrovirus Antibodies